Prosecution Insights
Last updated: November 04, 2026
Application No. 18/372,209

CELLULOSE DERIVATIVE FREE CAPSULE FOR HERBAL EXTRACTS

Final Rejection §103
Filed
Sep 25, 2023
Priority
Sep 27, 2022 — provisional 63/410,278
Examiner
COUGHLIN, DANIEL F
Art Unit
1619
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Gaia Herbs
OA Round
2 (Final)
39%
Grant Probability
At Risk
3-4
OA Rounds
6m
Est. Remaining
57%
With Interview

Examiner Intelligence

Grants only 39% of cases
39%
Career Allowance Rate
205 granted / 527 resolved
-21.1% vs TC avg
Strong +18% interview lift
Without
With
+17.8%
Interview Lift
resolved cases with interview
Typical timeline
3y 8m
Avg Prosecution
33 currently pending
Career history
569
Total Applications
across all art units

Statute-Specific Performance

§101
0.4%
-39.6% vs TC avg
§103
62.7%
+22.7% vs TC avg
§102
14.2%
-25.8% vs TC avg
§112
5.4%
-34.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 527 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined pursuant to the first inventor to file provisions of the AIA . DETAILED ACTION Status of the Claims The Examiner acknowledges receipt of Applicants’ Response, filed 20 July 2026. Claims 1, 2, and 8 are amended therein. Claims 7 - 13 remain withdrawn as being directed to a non-elected invention. Accordingly, claims 1 – 6 remain available for active consideration. REJECTIONS WITHDRAWN Rejections Pursuant to 35 U.S.C. § 112(b) The rejection pursuant to 35 U.S.C. § 112(b) set forth in the Action of 20 January 2026 is hereby withdrawn in light of Applicants’ amendment of the claims. REJECTIONS MAINTAINED Rejections Pursuant to 35 U.S.C. § 103 The following is a quotation of 35 U.S.C. § 103 that forms the basis for all obviousness rejections set forth in this Office Action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102 of this title, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. The factual inquiries set forth in Graham v. John Deere Co., 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103 are summarized as follows: 1. Determining the scope and contents of the prior art. 2. Ascertaining the differences between the prior art and the claims at issue. 3. Resolving the level of ordinary skill in the pertinent art. 4. Considering objective evidence present in the application indicating obviousness or nonobviousness. This application currently names joint inventors. In considering patentability of the claims the Examiner presumes that the subject matter of the various claims was commonly owned as of the effective filing date of the claimed invention absent any evidence to the contrary. Applicants are advised of the obligation pursuant to 37 CFR § 1.56 to point out the inventor and effective filing dates of each claim that was not commonly owned as of the effective filing date of the later invention in order for the Examiner to consider the applicability of 35 U.S.C. § 102(b)(2)(C) for any potential 35 U.S.C. § 102(a)(2) prior art against the later invention. The rejection of claims 1 – 6 pursuant to 35 U.S.C. § 103, as being obvious over US 2022/0273520 A1 to Kato, N. and M. Honda, published 1 September 2022, and claiming priority to 2 August 2019, identified on the Information Disclosure Statement (IDS) filed 25 September 2023, cite no. 7 (USPATAPP) (“Kato ‘520”), in view of US 2017/0216146 A1 to Hutchison, K. and T. Takubo, published 3 August 2017 (“Hutchison ‘146), and US 2023/0372252 A1 to Fang, Q. and K. Sukuru, published 23 November 2023, claiming priority to 16 October 2020 (“Fang ‘252”), is hereby maintained. The Invention As Claimed Applicants claim an organic or plant-based cellulose derivative free capsule encapsulating turmeric, the capsule comprising a capsule portion comprising organic pullulan, and a capsule content comprising turmeric as a powder, or as an aqueous alcoholic extract, and a mixture of plant-based oil and a plant-based lecithin, wherein the viscosity of the mixture of turmeric and plant-based oil and plant-based lecithin has a viscosity of about 1000 to 2500 cP at 25° C, wherein the ratio of plant-based oil to plant-based lecithin is about 4:1 to about 1:4 by weight, wherein the capsule further comprises an excipient, wherein the excipient is carnauba wax, and wherein the herbal material is extracted using supercritical extraction. The Teachings of the Cited Art Kato ‘520 discloses a capsule formulation in which a film of the capsule contains a base and a component other than the base, the base being one or more of gelatin, cellulose compounds, polyvinyl alcohol, polyvinyl alcohol copolymers and pullulan, and the component other than the base is one or more of gelling agents, gelation aids, plasticizers, lubricants, metal sequestering agents, coloring agents, light-shielding agents, and residual moisture (see ¶[0022]; see also, ¶[0081]), wherein the capsule formulation further comprises cottonseed oil-soybean oil mixtures (see ¶[0073]), and lecithin (see ¶[0075]), and, wherein the capsule formulation is prepared by producing a capsule film and content is then filled into the capsule film, wherein the lubricant can be carnauba wax (see ¶[0076]), and wherein the fill of the capsule formulation can include herbs such as turmeric extract (see ¶[0088]). The reference does not explicitly disclose a capsule formulation wherein the fill, in addition to the one or more pharmaceutically active ingredients, comprises a mixture of plant-based lecithin and a plant-based oil, with the fill having a viscosity of about 1000 to 2500 cP at 25° C. The teachings of Hutchison ‘146 and Fang ‘252 remedy those deficiencies. Hutchison ‘146 discloses a capsule fill formulation comprising an active ingredient and oil (see Abstract), wherein the oil comprises safflower oil, olive oil, soybean oil, linseed oil, rice germ oil, wheat germ oil, coconut oil, com oil, cottonseed oil, palm oil, palm nucleus oil, peanut oil, rapeseed oil, sesame oil, sunflower oil, almond oil, cashew oil, hazelnut oil, macadamia nut oil, mongongo oil, pecan oil, pine nut oil, pistachio oil, walnut oil, calabash seed oil, buffalo gourd oil, pumpkin seed oil, watermelon seed oil, acai berry extract, blackcurrant seed oil, borage seed oil, evening primrose oil, amaranth oil, apricot oil, apple seed oil, argan oil, artichoke oil, avocado oil, babassu oil, ben oil, cape chestnut oil, carob oil, cohune palm oil, coriander oil, dica oil, false flax oil, grape seed oil, hemp oil, kapok seed oil, lallemantia oil, marula oil, meadowfoam seed oil, mustard oil, okra seed oil (hibiscus oil), papaya oil, perilla oil, poppyseed oil, prune kernel oil, quinoa oil, ramtil oil, camellia oil, thistle oil, tomato oil, saw palmetto oil, lecithin, and combinations thereof (see ¶[0014]), wherein the amount of oil in the contents encapsulated in said the capsule is not less than 40% wgt (see ¶[0015]), wherein the active ingredient can include plant extracts (see ¶[0019]), wherein the plant extract is a turmeric extract (see ¶[0040]), wherein the lecithin in the oil is obtained from plants such as soy, rice, rapeseed, safflower, or the like (see ¶[0044]), and wherein the amount of oil with respect to all of the encapsulated content is included in an amount that can exert an expected degree of effect under given conditions (an active ingredient or the like, excipient, capsule, their capacity, or others), that amount ranging from 30 to 99.9% wgt, as can be determined by one skilled in the art according to the type of active ingredient and oil, with a higher amount of encapsulated oil being preferred (see ¶[0047]). Fang ‘252 discloses a controlled-release fill composition for use in hard or soft capsules, the fill composition including an active pharmaceutical ingredient, and two controlled-release components, wherein one of the components is present in an amount of at least 21.5% wgt and the other is present at up to 65% wgt (see Abstract), wherein controlled release softgel capsules deliver drug substances over a prolonged period of time from 8 to 24 hours (see ¶[0004]), wherein the active pharmaceutical ingredient may comprise from about 1 to about 60% wgt of the fill composition (see ¶[0016]), wherein any pharmaceutically active ingredient may be used in the compositions (see ¶[0116]), including herbal supplement active agents, such as turmeric (see ¶[0130]), wherein the ratio of the controlled release components of the fill composition may be adjusted to attain a target release profile for the API, such as from about 10:1 to about 1:10 (see ¶[0145]), wherein the loadings of the controlled release, and other, components can be adjusted so that the fill composition has a viscosity in the range of 1000 cP to 100,000 cP at 20° C (see ¶[0152]), wherein the dry shell accounts for about 30 to about 60% wgt, based on the total weight of the filled soft capsule, and the fill composition accounts for about 40 to about 70% wgt, based on the total weight of the filled capsule (see ¶[0156]), wherein an advantage of non-gelatin soft capsules is that higher encapsulation temperatures of up to 70° C can be employed in the encapsulation step to ensure that the fill composition is sufficiently flowable to allow for high viscosity fills (see ¶[0158]), wherein the fill composition may comprise one or more optional ingredients including surfactants, plasticizers, and release rate controlling components, such as carnauba wax (see ¶[0163]). Application of the Cited Art to the Claims It would have been prima facie obvious before the filing date of the claimed invention to prepare a capsule formulation in which a film of the capsule contains pullulan as a base, and a component other than the base, such as one or more of gelling agents, gelation aids, plasticizers, lubricants, metal sequestering agents, coloring agents, light-shielding agents, and residual moisture, wherein the lubricant is carnauba wax, wherein the capsule fill formulation further comprises cottonseed oil-soybean oil mixtures and lecithin, and wherein the fill of the capsule formulation includes herbs such as turmeric extract, as taught by Kato ‘520, wherein the capsule fill formulation comprises an active ingredient, such as turmeric extract and one or more oils, wherein the amount of oil in the fill composition of the capsule is not less than 40% wgt, wherein the lecithin in the oil is obtained from plants such as soy, rice, rapeseed, safflower, or the like, and wherein the amount of oil with respect to all of the encapsulated content is included in an amount that can exert an expected degree of effect under given conditions (an active ingredient or the like, excipient, capsule, their capacity, or others), that amount ranging from 30 to 99.9% wgt, as can be determined by one skilled in the art according to the type of active ingredient and type of oil, as taught by Hutchison ‘146, and wherein the fill composition includes at least two controlled-release components, wherein the active pharmaceutical ingredient, such as turmeric, may comprise from about 1 to about 60% wgt of the fill composition, wherein the ratio of the components of the fill composition may be adjusted to attain a target release profile for the API, wherein the loadings of the components of the fill composition can be adjusted so that the fill composition has a viscosity in the range of 1000 cP to 100,000 cP at 20° C, wherein an advantage of non-gelatin soft capsules is that higher encapsulation temperatures of up to 70° C can be employed in the encapsulation step to ensure that the fill composition is sufficiently flowable to allow for high viscosity fills, and wherein the fill composition includes carnauba wax, as taught by Fang ‘252. One of skill in the art would be motivated to do so, with a reasonable expectation of success in so doing, by the teachings of Hutchison ‘146 and Fang ‘252 to the effect that inclusion of oil components in the fill composition can be adjusted to achieve optimal clinical results, and to achieve targeted fill composition viscosities. With respect to the limitation recited in claim 1 directed to a range of viscosities of the capsule fill compositions, the Examiner notes that the cited references disclose a range of viscosities that encompasses the claimed range, rendering it obvious. See MPEP § 2144.05. “In the case where the claimed ranges ‘overlap or lie inside ranges disclosed by the prior art’ a prima facie case of obviousness exists. In re Wertheim, 541 F.2d 257, 191 USPQ 90 (CCPA 1976).” With respect to the limitation recited in claim 2 directed to the ratio between the oil and lecithin being about 4:1 to about 1:4, the Examiner notes that the cited references do not expressly disclose such ratios. However, the cited references disclose a range of relative mass content of the oil and lecithin components of the capsule fill compositions, and further disclose that the relative amounts of those components can be adjusted based on the identities of the oils and the active ingredient, as well as the desired clinical effect upon administration of the capsule dosage forms. Consequently, it is the Examiner’s position that adjustment of the relative mass loadings of the oil and the lecithin in the capsule fill compositions amounts to nothing more than an optimization of a result-effective variable, the exercise of which is well with the expertise of one of ordinary skill in the appropriate art. Consequently, in the absence of evidence as to the criticality of such parameter, this limitation cannot support patentability. See MPEP § 2144.05 II. A. With respect to claim 6, it is the Examiner’s position that the limitations recited therein are directed to the process used to prepare the turmeric extract, and not to any structural or compositional properties of the capsule of the invention, rendering it a product-by-process claim, wherein the recited process steps do not serve to distinguish the claimed invention from the prior art. See MPEP § 2113: Even though product-by process claims are limited by and defined by the process, determination of patentability is based on the product itself. The patentability of a product does not depend on its method of production. If the product in the product-by-process claim is the same as or obvious from a product of the prior art, the claim is unpatentable even though the prior product was made by a different process. In light of the forgoing discussion, the Examiner concludes that the subject matter defined by claims 1 – 6 would have been obvious within the meaning of 35 USC § 103. Response to Applicants’ Arguments The Examiner has considered the arguments offered by Applicants in their Response of 20 July 2026, but does not find them persuasive. Applicants argue that “the person of skill in the art would not combine the teachings of Fang, i.e., the loadings of the components of the fill compositions can be adjusted so that the fill composition has a viscosity in the range of 1000 cP to 100,000 cP at 20°C, with the teachings of Kato with a reasonable expectation of success.” Applicants base this assertion on the fact that Fang ‘252 “teaches that the amount of polyethylene oxide, as well as propylene glycol, in its compositions are adjusted to obtain its viscosities and are not attributed to an herbal extract or mixture of plant-based oil and plant-based lecithin.” It is the Examiner’s position that Applicants base their argument on an improperly narrow interpretation of the scope of the claims in question. More specifically, Applicants appear to base their argument on a reading of claim 1 that states that the viscosity of the capsule fill arises only from the oil and lecithin components of the fill. First of all, the Examiner notes that claim 1 makes use of the open-ended “comprising” term in addressing the “capsule content” (see claim 1. a.). Thus, the plain language of the claim allows for the presence of additional components in the capsule fill, and not just herbal extracts, plant-based oil, and plant-based lecithin. The claim clearly can be read to encompass the polyethylene oxide and propylene glycol disclosed by Fang ‘252. To give Applicants’ argument credence sufficient to overcome the prima facie case of obviousness set forth above, would require an interpretation of claim 1 that effectively treats the claim as comprising a limitation directed to the specific method used to achieve a viscosity within the claimed range. In that case, the claim would, in practice, be a product-by-process claim, in which process steps are not afforded patentable weight. See MPEP § 2113. However, the fact that Applicants have recognized another advantage which would flow naturally from following the suggestion of the prior art cannot be the basis for patentability when the differences would otherwise be obvious. See Ex parte Obiaya, 227 USPQ 58, 60 (Bd. Pat. App. & Inter. 1985). In this regard, Applicants are reminded that the invention as claimed is directed to a composition of matter, and that, as a consequence, the reasons for combining the teachings of cited references, are not necessarily controlling to the patentability of the compositions, as claimed. The reason or motivation to modify the reference may often suggest what the inventor has done, but for a different purpose or to solve a different problem. It is not necessary that the prior art suggests the combination to achieve the same advantage or result discovered by applicant. See, e.g., In re Kahn, 441 F.3d 977, 987, 78 USPQ2d 1329, 1336 (Fed. Cir. 2006). Applicants also make numerous references to specific disclosures from Fang ‘252 directed to the presence of PEO and propylene glycol and their roles in the fill composition, including adjustment of viscosity. However, these cites do not change the fact that claim 1 only requires that the capsule fill, comprising an herbal extract, an oil, and lecithin, display a viscosity with the recited numerical range. It does not require that the viscosity of the fill arises from only the combination of herbal extract, oil, and lecithin. Consequently, based on the above discussion, Applicants’ arguments are unpersuasive, and claims 1 – 6 stand rejected as obvious pursuant to 35 U.S.C. § 103. NO CLAIM IS ALLOWED. THIS ACTION IS MADE FINAL. Applicants are reminded of the extension of time policy as set forth in 37 CFR § 1.136(a). PNG media_image1.png 18 19 media_image1.png Greyscale A shortened statutory period for reply to this Final Action is set to expire THREE MONTHS from the mailing date of this action. In the event a first Response is filed within TWO MONTHS of the mailing date of this Final Action and the Advisory Action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the Advisory Action is mailed, and any extension fee pursuant to 37 CFR § 1.136(a) will be calculated from the mailing date of the Advisory Action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this Final Action. CONCLUSION Any inquiry concerning this communication or any other communications from the Examiner should be directed to Daniel F. Coughlin whose telephone number is (571)270-3748. The Examiner can normally be reached on M - F 8:30 a.m. - 5:00 p.m. If attempts to reach the Examiner by telephone are unsuccessful, the Examiner’s supervisor, David Blanchard, can be reached on (571)272-0827. The fax phone number for the organization where this application or proceeding is assigned is (571)273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. /DANIEL F COUGHLIN/ Examiner, Art Unit 1619 /DAVID J BLANCHARD/ Supervisory Patent Examiner, Art Unit 1619
Read full office action

Prosecution Timeline

Sep 25, 2023
Application Filed
Jan 20, 2026
Non-Final Rejection mailed — §103
Jul 20, 2026
Response Filed
Aug 27, 2026
Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12779087
BONE REGENERATION MATERIAL
4y 10m to grant Granted Nov 03, 2026
Patent 12741128
MICRONEEDLE PARTICLES, COMPOSITIONS, AND METHODS OF TREATMENT AND DELIVERING A SUBSTANCE OF INTEREST
2y 2m to grant Granted Sep 22, 2026
Patent 12734128
GASTRIC RESIDENCE SYSTEMS HAVING A FILAMENT FOR IMPROVED GASTRIC RESIDENCE
4y 4m to grant Granted Sep 15, 2026
Patent 12714571
POROUS COMPOSITE BIOMATERIALS AND RELATED METHODS
2y 2m to grant Granted Aug 25, 2026
Patent 12691200
BONE GRAFT COMPOSITION
4y 0m to grant Granted Jul 28, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
39%
Grant Probability
57%
With Interview (+17.8%)
3y 8m (~6m remaining)
Median Time to Grant
Moderate
PTA Risk
Based on 527 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month